Ultragenyx Pharmaceutical Target of Unusually High Options Trading (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was the recipient of some unusual options trading activity on Tuesday. Stock traders purchased 5,997 put options on the company. This is an increase of approximately 240% compared to the typical daily volume of 1,764 put options.

Ultragenyx Pharmaceutical Stock Down 1.3%

NASDAQ RARE opened at $23.88 on Thursday. The business’s fifty day simple moving average is $27.49 and its 200-day simple moving average is $29.83. The firm has a market cap of $2.30 billion, a PE ratio of -4.02 and a beta of 0.16. Ultragenyx Pharmaceutical has a 52 week low of $18.41 and a 52 week high of $46.27.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,061 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $23.56, for a total transaction of $72,117.16. Following the completion of the transaction, the chief financial officer directly owned 88,935 shares in the company, valued at approximately $2,095,308.60. This represents a 3.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 6,227 shares of company stock valued at $187,126. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors have recently made changes to their positions in the company. Covestor Ltd grew its position in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 369 shares during the period. Huntington National Bank grew its holdings in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the period. Teacher Retirement System of Texas increased its position in shares of Ultragenyx Pharmaceutical by 1.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after purchasing an additional 404 shares during the last quarter. Xponance Inc. raised its holdings in Ultragenyx Pharmaceutical by 3.1% in the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 406 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Ultragenyx Pharmaceutical by 2.3% in the second quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock valued at $690,000 after buying an additional 434 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Multiple plaintiff law firms have announced or reminded investors of a securities class-action covering purchases from August 3, 2023 through December 26, 2025 and the April 6, 2026 deadline to seek lead-plaintiff status; these releases increase the chance of consolidated litigation and media attention. Class Action Announcement for Ultragenyx Pharmaceutical Inc. (RARE): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Ultragenyx. Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
• Negative Sentiment: The class action complaint alleges material misstatements and/or omissions about Ultragenyx’s drug setrusumab — if the claims proceed, litigation costs, management distraction and potential damages could materially affect valuation and investor sentiment. Class Action Announcement for Ultragenyx Pharmaceutical Inc. (RARE): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Ultragenyx.
• Negative Sentiment: Unusually large put-option activity: traders bought 5,997 put options on Feb. 10 (about a 240% jump vs. average), signaling increased bearish bets and potential for amplified downside volatility in the near term.
• Negative Sentiment: Technical backdrop is weak — the stock is below both its 50-day ($27.49) and 200-day ($29.83) moving averages, which can deter momentum investors and trigger additional selling.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Bank of America reduced their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, January 2nd. Leerink Partners reduced their target price on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Barclays decreased their target price on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, November 24th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 3rd. Finally, Guggenheim decreased their price objective on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a report on Monday, January 5th. Sixteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $72.29.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.